SCHEMBL2173312

SCHEMBL2173312

Cn1nc(C(=O)Nc2cccc(Cl)c2)c2c1-c1cc(Cl)ccc1OC2

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.61
POLB P06746 3/20 0.61
TP53 P04637 2/20 0.55
NR1H4 Q96RI1 3/20 0.54
ALDH1A1 P00352 3/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
HPGD P15428 2/20 0.50
KDM4E B2RXH2 2/20 0.50
LMNA P02545 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
THRB P10828 2/20 0.49
MAOB P27338 2/20 0.45
MAOA P21397 1/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
APEX1 P27695 1/20 0.44
GRM5 P41594 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2546279 0.92 MAPT (0.55) MAPTPOLBTP53NR1H4ALDH1A1
SCHEMBL2547296 0.92 MAPT (0.69) MAPTPOLBTP53NR1H4ALDH1A1
SCHEMBL2171108 0.85 MAPT (0.79) MAPTPOLBTP53NR1H4MEN1
SCHEMBL2546275 0.82 NR1H4 (0.65) MAPTPOLBTP53NR1H4
SCHEMBL2172534 0.82 MAPT (0.68) MAPTPOLBTP53NR1H4LMNA
SCHEMBL22299180 0.81 NR1H4 (0.57) MAPTPOLBTP53NR1H4
SCHEMBL2186610 0.80 MAPT (0.72) MAPTPOLBTP53ALDH1A1HPGD
SCHEMBL2186582 0.80 THRB (0.52) MAPTPOLBTP53ALDH1A1MEN1
SCHEMBL2542966 0.78 MAPT (0.70) MAPTPOLBTP53ALDH1A1MEN1
SCHEMBL2171100 0.78 MAPT (0.69) MAPTPOLBTP53MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110263588-A1 TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2011-10-27 US claimed
US-20110263588-A1 TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2011-10-27 US disclosed
US-20110263588-A1 TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2011-10-27 US disclosed
US-20110263588-A1 TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2011-10-27 US disclosed
EP-2346832-A1 TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS Glaxo Group Limited (GB) 2011-07-27 EP disclosed
WO-2010049366-A1 TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2010-05-06 WO disclosed
WO-2010049366-A1 TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2010-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263588-A1 TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS GRM5, GRM1, GRM3 MAPT 2044/4885POLB 4360/4885TP53 4565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.